

[EBMT](#)

[Annual report](#)

[2022](#)



[ScienceEducationPatient Care & Advocacy](#)

[Our SocietyOur Mission, Vision & ValuesEquality, Diversity & InclusionEBMT](#)


[Membership 2022Organisational Structure 2022Financial Highlights 2022EBMT](#)

[Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print



Donal McLornan

CMWP Chair (ELECTED MARCH 2022, PREVIOUS CHAIR: Ibrahim Yakoub-Agha)

United Kingdom

## Major achievements

In Spring 2022, Dr. Donal McLornan from University College Hospital, London, UK, became the new chair of the CMWP, overtaking the role of Professor Ibrahim Yakoub-Agha, Lille, France, who served as chair of the party for the previous 4 years. The scientific structure of CMWP was reorganised slightly to provide the best

possible coverage and further develop collaboration with other WPs. As such a new subcommittee, CAR-T in multiple myeloma was created, which will work closely in collaboration with the CTIWP, and the MDS group was further reorganised to include an emerging focus on VEXAS with MDS. The CMWP, in collaboration with the AIDWP, are working closely with the autoimmune/rheumatology specialists within AIDA due to a new and exciting AIDA-EBMT alliance. A joint application for funding for development of guidelines with a focus on VEXAS therapy including transplant has been submitted to EULAR.

The CMWP members finally had a chance to have a face-to-face meeting between the 30th of September – 1st of October 2022 in Milan, Italy. The meeting was a tremendous occasion to focus on – and refine- our extensive research project portfolio during the scientific business meeting. The educational part focused on somatic mutations and their impact on the outcome of allo-HCT in MDS patients, as well as on the role of MRD in MDS, the placing of CAR-T and auto-HCT in the treatment of multiple myeloma, optimising haploidentical allo-HCT in myelofibrosis as well as new non-transplant strategies for myelofibrosis, the role of NGS for kinase domain (KD) mutational analysis in CML and the role of CAR-T in the treatment of CLL.

2022 was also a year when the whole CMWP team re-energized our focus on prioritising and finalising the already initiated projects, with 22 published papers and a further 4 papers under review by the end of the year. We thank everyone involved and, in particular, the CMWP Data Management/Programming team and statistician experts.

## **Principal research studies**

[GvHD Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the CMWP of the EBMT.](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Chronic Myeloid Leukaemia \(CML\)](#)

[Myelodysplastic \(MDS\) or MDS/MPN](#)

[Myeloproliferative Neoplasm \(MPN\)](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

Type of Stem Cell Treatment

Allogeneic

Principal investigator

Thomas Luft

Outcomes of Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with CALR-Mutated Myelofibrosis compared to those patients with a JAK2-mutation.

Study type

Retrospective Studies

Diseases

Myeloproliferative Neoplasm (MPN)

Group

Chronic Malignancies Working Party (CMWP)

Type of Stem Cell Treatment

Allogeneic

Principal investigator

Juan Carlos Hernández-Boluda

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres.

Study type

Retrospective Studies

Diseases

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Group

Chronic Malignancies Working Party (CMWP)

Type of Stem Cell Treatment

Autologous

Principal investigator

Patrick Hayden

Outcomes following the use of PTCy in URD allo-HCT for CML

Study type

Retrospective Studies

Diseases

Chronic Myeloid Leukaemia (CML)

Group

Chronic Malignancies Working Party (CMWP)

Type of Stem Cell Treatment

Allogeneic - Unrelated

[Principal investigator](#)

[Guillermo Orti](#)

[Allo-HCT in CLL after multiple pathway inhibitors.](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Chronic Lymphocytic Leukaemia \(CLL\)](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of Stem Cell Treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Michel van Gelder/Olivier Tournilhac](#)

## **Key publications**

[2022](#)

[Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of](#)

[EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Kavita Raj](#)

[Journal](#)

[Blood Cancer J.](#)

[2022](#)

[Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Nicola Polverelli](#)

[Journal](#)

[Lancet Haematol.](#)

[2022](#)

[Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Yves Chalandon](#)

[Journal](#)

[Am J Hematol.](#)

[2022](#)

[Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Sarah Lawless](#)

[Journal](#)

[Haematologica.](#)

[2022](#)

[Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Dai Chihara](#)


[Journal](#)

[Haematologica.](#)

[See the full list of the CMWP 2022 publications](#)



Impact factor  
(Chronic Malignancies)



**2019 2020 2021 2022**

<b>Oral presentations</b>	<b>9</b>	<b>1</b>	<b>7</b>	<b>9</b>
<b>Poster presentations</b>	<b>8</b>	<b>12</b>	<b>5</b>	<b>8</b>
<b>Educational events</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>

**Major educational events**



[Event](#)

## [Virtual 48th Annual Meeting of the EBMT](#)



[Event](#)

## [Chronic Malignancies Working Party Educational Meeting](#)



[Event](#)

## [Chronic Malignancies Working Party Educational Meeting](#)

[Oct 01, 2022 - Oct 01, 2022 / Milan, Italy](#)

[Discover more](#)

[VISIT THE CMWP WEBPAGE](#)